17ß-Hydroxysteroid dehydrogenase type 1 as predictor of tamoxifen response in premenopausal breast cancer

European Journal of Cancer

Volumn 46, Issue 5, 2010, Pages 892-900

  Källström, Ann Christine ^a,b   Salme, Rebecka ^b   Rydén, Lisa ^c   Nordenskjöld, Bo ^b   Jönsson, Per Ebbe ^a,c   Stål, Olle ^b  

^a HELSINGBORG HOSPITAL   (Sweden)

^b LINKÖPING UNIVERSITY   (Sweden)

^c LUND UNIVERSITY   (Sweden)

Author keywords

17 Hydroxysteroid dehydrogenases; Breast cancer; HSD17B1; Oestrogens; Predictive marker; Premenopausal women; Tamoxifen; Treatment prediction

Indexed keywords

CYCLOPHOSPHAMIDE; FLUOROURACIL; GOSERELIN; METHOTREXATE; TAMOXIFEN; TESTOSTERONE 17BETA DEHYDROGENASE; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; HYDROXYSTEROID DEHYDROGENASE;

ADJUVANT THERAPY; ADULT; ARTICLE; BREAST CANCER; CANCER INVASION; CANCER MORTALITY; CANCER RECURRENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PREMENOPAUSE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; TREATMENT RESPONSE; ADJUVANT CHEMOTHERAPY; BIOSYNTHESIS; BREAST TUMOR; ENZYMOLOGY; MIDDLE AGED; PATHOLOGY; PROSPECTIVE STUDY; RISK FACTOR; TREATMENT OUTCOME; TUMOR RECURRENCE;

17-HYDROXYSTEROID DEHYDROGENASES; ADULT; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PREMENOPAUSE; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS; TAMOXIFEN; TREATMENT OUTCOME;

EID: 77349107688     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2009.12.016     Document Type: Article

References (30)

1. McGuire W.L. Current status of estrogen receptors in human breast cancer. Cancer 36 (1975) 638-644
2. Hawkins R.A., and Oakey R.E. Estimation of oestrone sulphate, oestradiol-17beta and oestrone in peripheral plasma: concentrations during the menstrual cycle and in men. J Endocrinol 60 (1974) 3-17
3. Sasano H., Suzuki T., Nakata T., and Moriya T. New development in intracrinology of breast carcinoma. Breast Cancer 13 (2006) 129-136
4. Pasqualini J.R., and Chetrite G.S. Recent insight on the control of enzymes involved in estrogen formation and transformation in human breast cancer. J Steroid Biochem Mol Biol 93 (2005) 221-236
5. Gunnarsson C., Olsson B.M., and Stal O. Abnormal expression of 17beta-hydroxysteroid dehydrogenases in breast cancer predicts late recurrence. Cancer Res 61 (2001) 8448-8451
6. Miyoshi Y., Ando A., Shiba E., et al. Involvement of up-regulation of 17beta-hydroxysteroid dehydrogenase type 1 in maintenance of intratumoral high estradiol levels in postmenopausal breast cancers. Int J Cancer 94 (2001) 685-689
7. Oduwole O.O., Li Y., Isomaa V.V., et al. 17Beta-hydroxysteroid dehydrogenase type 1 is an independent prognostic marker in breast cancer. Cancer Res 64 (2004) 7604-7609
8. Gunnarsson C., Hellqvist E., and Stal O. 17Beta-hydroxysteroid dehydrogenases involved in local oestrogen synthesis have prognostic significance in breast cancer. Brit J Cancer 92 (2005) 547-552
9. Jansson A., Delander L., Gunnarsson C., et al. Ratio of 17HSD1 to 17HSD2 protein expression predicts the outcome of tamoxifen treatment in postmenopausal breast cancer patients. Clin Cancer Res 15 (2009) 3610-3616
10. Peltoketo H., Isomaa V., Poutanen M., and Vihko R. Expression and regulation of 17 beta-hydroxysteroid dehydrogenase type 1. J Endocrinol 150 Suppl (1996) S21-S30
11. Luu-The V., Zhang Y., Poirier D., and Labrie F. Characteristics of human types 1, 2 and 3 17 beta-hydroxysteroid dehydrogenase activities: oxidation/reduction and inhibition. J Steroid Biochem Mol Biol 55 (1995) 581-587
12. Miettinen M.M., Mustonen M.V., Poutanen M.H., Isomaa V.V., and Vihko R.K. Human 17 beta-hydroxysteroid dehydrogenase type 1 and type 2 isoenzymes have opposite activities in cultured cells and characteristic cell- and tissue-specific expression. Biochem J 314 (1996) 839-845
13. Soderqvist G., Poutanen M., Wickman M., et al. 17Beta-hydroxysteroid dehydrogenase type 1 in normal breast tissue during the menstrual cycle and hormonal contraception. J Clin Endocrinol Metab 83 (1998) 1190-1193
14. Gunnarsson C., Jerevall P.L., Hammar K., et al. Amplification of HSD17B1 has prognostic significance in postmenopausal breast cancer. Breast Cancer Res Treat 108 (2008) 35-41
15. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687-717.
16. Ryden L., Jonsson P.E., Chebil G., et al. Two years of adjuvant tamoxifen in premenopausal patients with breast cancer: a randomised, controlled trial with long-term follow-up. Eur J Cancer 41 (2005) 256-264
17. Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. Swedish Breast Cancer Cooperative Group. J Natl Cancer Inst 1996;88:1543-9.
18. Ryden L., Landberg G., Stal O., et al. HER2 status in hormone receptor positive premenopausal primary breast cancer adds prognostic, but not tamoxifen treatment predictive, information. Breast Cancer Res Treat 109 (2008) 351-357
19. Stendahl M., Ryden L., Nordenskjold B., et al. High progesterone receptor expression correlates to the effect of adjuvant tamoxifen in premenopausal breast cancer patients. Clin Cancer Res 12 (2006) 4614-4618
20. Labrie F., Luu-The V., Labrie C., et al. Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone. Endocr Rev 24 (2003) 152-182
21. Nguyen B.L., Chetrite G., and Pasqualini J.R. Transformation of estrone and estradiol in hormone-dependent and hormone-independent human breast cancer cells. Effects of the antiestrogen ICI 164, 384, danazol, and promegestone (R-5020). Breast Cancer Res Treat 34 (1995) 139-146
22. Poutanen M., Moncharmont B., and Vihko R. 17Beta-hydroxysteroid dehydrogenase gene expression in human breast cancer cells: regulation of expression by a progestin. Cancer Res 52 (1992) 290-294
23. Suzuki T., Moriya T., Ariga N., et al. 17Beta-hydroxysteroid dehydrogenase type 1 and type 2 in human breast carcinoma: a correlation to clinicopathological parameters. Brit J Cancer 82 (2000) 518-523
24. Cui X., Schiff R., Arpino G., Osborne C.K., and Lee A.V. Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. J Clin Oncol 23 (2005) 7721-7735
25. Yang S., Fang Z., Gurates B., et al. Stromal PRs mediate induction of 17beta-hydroxysteroid dehydrogenase type 2 expression in human endometrial epithelium: a paracrine mechanism for inactivation of E2. Mol Endocrinol (2001) 2093-2105
26. Pasqualini J.R. Differential effects of progestins on breast tissue enzymes. Maturitas 46 (2003) S45-S54
27. Mustonen M.V., Isomaa V.V., Vaskivuo T., et al. Human 17beta-hydroxysteroid dehydrogenase type 2 messenger ribonucleic acid expression and localization in term placenta and in endometrium during the menstrual cycle. J Clin Endocrinol Metab 83 (1998) 1319-1324
28. Kitawaki J., Koshiba H., Ishihara H., et al. Progesterone induction of 17beta-hydroxysteroid dehydrogenase type 2 during the secretory phase occurs in the endometrium of estrogen-dependent benign diseases but not in normal endometrium. J Clin Endocrinol Metab 85 (2000) 3292-3296
29. Dowsett M., Cuzick J., Wale C., et al. Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study. J Clin Oncol 23 (2005) 7512-7517
30. Day J.M., Tutill H.J., Purohit A., and Reed M.J. Design and validation of specific inhibitors of 17beta-hydroxysteroid dehydrogenases for therapeutic application in breast and prostate cancer, and in endometriosis. Endocr Relat Cancer 15 (2008) 665-692